Friedreich's Ataxia (FRDA) is caused by a homozygous intronic GAA expansion in the FXN gene. FRDA affects primarily the peripheral nervous system (PNS) with cumulative evidence from postmortem studies and in vitro models suggesting a developmental component of its pathology. In the present study, we aimed at gaining further insight in the PNS involvement in FRDA by investigating small nerve fibers in vivo. For this purpose, we evaluated the intraepidermal nerve fiber (IENF) density in skin-biopsies of the lower leg and applied clinical assessments of small fiber function (painDE-TECT, quantitative sensory testing) in 17 FRDAs. Mean IENF density was significantly lower in FRDAs compared to controls (5.77 6 4.68 vs 9.33 6 1.41, p ¼ 0.013). Clinically, cold detection threshold was decreased in FRDAs (FRDA ¼ À3.47(À6.64; À3.14), controls ¼ À1.71 (À3.43; À1.23), p ¼ 0.001) while other measures of small fiber function such as warm and pain sensation thresholds did not differ from controls. Five patients had sensory complaints, but none was diagnosed with neuropathic pain at painDETECT. The degree of small fiber loss was markedly variable in our cohort and showed an inverse correlation with the GAA repeat length (R 2 ¼ 0.573, p ¼ 0.001). Our findings support a genetically determined small fiber loss in FRDA.
INTRODUCTION
Friedreich ataxia (FRDA) is an autosomal recessive movement disorder that manifests with progressive gait instability, coordination disturbances, and sensory loss (1) . Scoliosis, pes cavus, hypertrophic cardiomyopathy, and diabetes mellitus also belong to the phenotypic spectrum (1) . FRDA is caused in the vast majority of cases by a homozygous GAA triplet expansion in the first intron of the FXN gene (2) . FXN codes for frataxin, a mitochondrial protein involved in the iron-sulfur cluster biogenesis (3) . Pathologic GAA expansions hinder FXN expression resulting in frataxin deficiency (4) . A correlation exists between GAA repeat length, frataxin level, and clinical severity. Indeed the majority of studies showed that longer repeats in the shorter GAA expansion (GAA1) result in earlier disease onset and more severe phenotype (1, 5, 6) . The age at onset is in turn related to disease progression. Clinically, an early onset group with fast progression and a late-onset group with milder worsening over time are identified (6) .
FRDA affects primarily the peripheral nervous system with the crucial lesions residing in the dorsal root ganglia (DRG), dorsal spinal roots, and peripheral nerves (7) (8) (9) (10) . Degeneration of posterior columns in the spinal cord occurs secondary to DRG pathology, while neurodegeneration of nucleus dentatus cerebelli and corticospinal pathway represents the only intrinsic central lesions (7) . How the deficiency of frataxin leads to this selective neuropathology remains largely an unsolved issue (11) . At autopsy, hypoplastic features are evident in DRG and spinal cord of FRDA (8) . Accordingly, experimental evidence accumulated that FRDA pathology starts early during ontogenesis (12, 13) . The total absence of frataxin is lethal to the embryo in the murine model (12) . Furthermore, a study on induced pluripotent stem cells showed that neural crest cells derived from FRDA patients fail to upregulate frataxin during the differentiation in peripheral sensory neurons (13) .
In the present study, we aimed at providing further insight in the pathology of peripheral nervous system involvement in FRDA by investigating the small unmyelinated intraepidermal nerve fibers. Biopsies of dorsal root ganglia intra vitam are not feasible and postmortem specimens are scarce, whereas skin biopsies can be easily sampled (14) . In a pioneer work, Nolano et al demonstrated a marked reduction of unmyelinated nerve fibers in punch skin biopsies of FRDA patients (15) . However, this early observation was limited to patients with large GAA expansion and advanced disease, thus preventing from inferring on the pathophysiology of this finding.
The objective of the present study is a neuropathological and clinical evaluation of small nerve fibers in a representative cohort of FRDA with different genotypic and phenotypic severity in order to identify correlations between small fiber pathology, genetic features, and clinical milestones.
MATERIALS AND METHODS

Ethics and Screening Procedures
The study was approved by the local ethics committee (Innsbruck Medical University, Study number: AN2016-0153).
All examinations were conducted in accordance with the declaration of Helsinki on ethical principles for medical research involving human subjects. Genetically confirmed FRDA patients were consecutively enrolled in the Ataxia outpatient clinic of the Neurology department at Innsbruck Medical University. Each patient signed written informed consent prior to enrollment. Patients underwent a screening evaluation including an in-depth anamnesis and laboratory work-up (including HbA1c, Vitamin B 12 , and folate) aimed at excluding secondary causes of small fiber pathology. Diabetes mellitus or impaired glucose metabolism, defined as HbA1c level !6%, vitamin B 12 deficiency, and folate deficiency were set as exclusion criteria. Genetic testing of patients was performed in local laboratories. GAA repeat lengths were confirmed by a second independent laboratory.
Twenty-eight age-and sex-matched healthy control subjects that underwent the quantitative sensory testing were recruited locally. There was no ataxia or sign of neuropathy upon clinical examination. A subset of above-mentioned healthy control subjects was recruited for skin biopsy (n ¼ 9).
Neurological Examination
Each patient underwent a general and neurological examination. The severity of neurological involvement was determined with the validated scale for rating and assessment of ataxia (SARA) (16) . The SARA evaluates ataxia of gait and stance, dysmetria in both upper and lower extremities, intentional tremor, and dysdiadochokinesia to yield a final score between 0 (¼ absence of ataxia) and 40 (¼ the most severe ataxia). We recorded the presence of "pes cavus" (i.e. a distinctly hollow foot sole when bearing weight). Neuropathic symptoms were investigated by means of in-depth clinical interview and a standardized questionnaire, the painDETECT. Patients were specifically asked if they suffered from dysesthesias/hyperesthesia of lower extremities and the painDE-TECT questionnaire was applied to capture the presence of neuropathic pain. The painDETECT evaluates both intensity and characteristic of pain (e.g. continuous pain vs pain attacks, presence of burning sensation, and allodynia) to establish a final score between 0 and 38. A final score between 0 and 12 indicates absence of neuropathic component; between 12 and 18 unclear neuropathic component; and >19 likely neuropathic component of pain complaints (17) .
Quantitative Sensory Testing
The Quantitative Sensory Testing (QST) was applied to assess thermal, mechanical, and pain perception. We assessed 7 parameters using the method of limits: cold detection threshold (CDT), cold pain threshold (CPT), warm detection threshold (WDT), warm pain threshold (WPT), mechanical detection threshold (MDT), mechanical pain threshold (MPT), wind-up ratio (WUR), and vibration detection threshold (VDT) (18) . Thermal detection and thermal pain thresholds were assessed using a TSA II Neurosensory Analyzer (Medoc, Israel) with a Peltier thermode with 9 cm 2 contact area which is placed on the dorsum pedis. All thresholds were obtained using ramped stimuli at a velocity of 1 C/second. The output temperature was 32 C and thresholds are expressed as deltas from this value (e.g. if patient perceived cold at 30 C, CDT ¼ À2). Mechanical detection thresholds were determined with a standardized set of modified von Frey hairs (Somedic, Sös-dala, Sweden). Mechanical pain thresholds were measured using a set of 7 pinprick devices with fixed stimulus intensities that exert forces of 8, 16, 32, 64, 128, 256, and 512 mN. Temporal summation of pain sensation (perceptual wind-up) was assessed by 5 consecutive trains of 10 pin-prick stimuli at a repetition frequency of 1/second and an intensity of 256 mN. For measurement of vibration detection threshold, a 128 Hz tuning fork was used, and the average value of 3 consecutive measures was considered. QST measurements were conducted in accordance to the standardized protocol of the German research network on neuropathic pain (19) . The assessment was conducted on patients most affected side. For each QST threshold, 1 FRDA was compared with 2 age-and sexmatched healthy controls from our laboratory.
Intraepidermal Nerve Fiber Evaluation
Three-millimeter punch skin biopsies were obtained from 15 FRDA patients at the distal leg, 10 cm above the lateral malleolus, after subcutaneous injection of 1% mepivacaine. The biopsy was performed on the same side as QST. Two patients did not give consent to the intervention. Skin biopsies were fixed in buffered 4% paraformaldehyde solution immediately after removal for 30 minutes at room temperature, washed 3 times with PBS and transferred to cryoprotective 10% sucrose solution for at least 24 hours at 4 C. Subsequently, the biopsies were snap-frozen in liquid nitrogen and stored at À80 C. Forty lm thick frozen sections were stained with hematoxylin and eosin and immunostained for the pan-axonal marker protein gene product 9.5 (PGP 9.5, rabbit polyclonal antibody, #UltraClone Limited) for evaluation with immunofluorescence. The antibody was diluted 1:400 in 1% BSA and 0.3% Triton-X and applied to the sections overnight at 4 C. On the following day, sections were washed 3 times with PBS and incubated with Alexa Fluor 488 goat-antirabbit IgG (L þ H) for 60 minutes at room temperature (diluted 1:400; Invitrogen). Samples were covered with Vectashield mounting medium containing 4 0 ,6-diamidino-2-phenylindole (H-1200; Vector Laboratories, Burlingame, CA) and analyzed with a conventional fluorescence microscope (Leica DFC300 FX). Quantification of epidermal nerve fiber densities was performed according to the recommendations of the guidelines of the European Federation of Neurological Societies/Peripheral Nerve Society evaluating at least 3 sections (14) . Values of intraepidermal nerve fiber (IENF) densities are reported as average number of fibers per millimeter. IENF density in FRDAs was compared with 9 (female ¼ 4, male ¼ 5) age-and sex-matched healthy controls from our laboratory. On the basis of age-and gender-adjusted normative values that had been published recently (20) , we defined 4 categories to describe the severity of biopsy findings: (i) normal IENF density (accounts for IENF value >5 quantile for the respective age and sex category), (ii) intermediate IENF reduction (accounts for IENF value <5 quantile for the respective age and sex category, but still preserved intraepidermal innervation), (iii) severe IENF reduction (single intraepidermal nerve
fibers) with preserved subepidermal plexus, and (iv) depletion of fibers both in the epidermis and subepidermal plexus.
Statistical Analysis
Statistical analysis was performed with SPSS version 24. First, a descriptive statistics was carried out and categorical variables were reported as percentages. Distribution of quantitative variables was tested by means of KolmogorovSmirnov test. They were then reported as mean 6 SD or as median (interquartile range) as required by their distribution. Comparisons of QST parameters and IENF density values between patients and controls or patient subgroups were performed by means of unpaired t-test or Mann-Whitney U-test, according to variables distribution. We applied a multistep linear regression model to estimate the influence of age at examination, disease duration, disease severity (expressed by SARA), and GAA1 repeats on the IEFN density. Statistical significance was set at p < 0.05. Table. Mean age at examination was 37 6 11 years and mean SARA score was 21 6 8 out of 40 points. Mean GAA1 was 468 6 215 number of repeats. Mean age at onset was 21 6 12 years, 5 patients (29.4%) had disease onset >25 years of age.
RESULTS
Twenty
Eight patients (47%) had pes cavus. Dysesthesia/hyperesthesia of lower legs and/or feet were reported by 5 patients (29.4%). Of them, 4 reported pain at painDETECT (scores were 6, 6, 8, and 18, respectively). Pain was described as "burning" in the foot soles by 1 patient and as tingling by 2 patients; another patient perceived cold temperature and application of pressure as painful. All other patients had a score of 0 at painDETECT.
Quantitative Sensory Testing
All patients underwent QST, though some assessments could not be completed in each patient. The assessment of thermic thresholds was not possible in 1 patient because of severe disease with distal paresis of upper arms (patients are required to click on a mouse during the assessment) and in 2 patients it was not conducted because of technical reasons. One patient refused the MPT and WUR examinations because of foot hypersensitivity.
In the thermal perception assessment, only the CDT significantly differed between patients and controls, that is, patients recognized the cold sensation at lower temperatures of the thermode (CDT_FRDA ¼ À3.47 (À6.64; À3.14), CDT_controls ¼ À1.71 (À3.43; À1.23), p ¼ 0.001). All other thermic thresholds did not significantly differ between patients and controls (Fig. 1) 
Intraepidermal Nerve Fiber Evaluation
Mean IENF density in FRDA was significantly lower compared to controls (FRDA ¼ 5.77 6 4.68 vs controls ¼ 9.33 6 1.41, p ¼ 0.013). Notably, the degree of nerve fiber loss in FRDA was highly variable. According to our predefined categories, 3 patients showed a normal IENF density; 6 patients had an intermediate reduction, and 5 patients had a severe reduction of IENF density. A depletion of nerve fibers both in the epidermis and in the subepidermal plexus was detected in 1 patient (Fig. 2) . Apart from reduced nerve fiber densities, patient biopsies showed further qualitative abnormal findings such as fragmented and swollen intraepidermal axons. Reduced innervation of sweat glands was also observed (Fig. 2) .
IENF density was significantly lower in early-onset FRDA compared to late onset cases (median value 1.7 (1.35; 6.35) and 8.8 (7.65; 11), respectively; p ¼ 0.026) and in patients with pes cavus compared with those without (1.6 6 1.4 and 7.8 6 4.4, respectively; p ¼ 0.009) In patients with neuropathic complaints (n ¼ 5), IENF density was highly variable (median value 1.7 (1.25; 10.1)) and no significant difference could be shown in the comparison with the other patients (n ¼ 10, 6.0 (1.5; 10.1), p ¼ 0.622).
In a multistep regression analysis, age at examination, disease duration, and severity had no influence on IENF density. Though, a correlation was found between IENF density values and the shorter GAA repeat in FRDA patients (R 2 ¼ 0.573, p ¼ 0.001, Fig. 3 ).
DISCUSSION
In the present study, we investigated small nerve fiber pathology in FRDA by means of a neuropathological and clinical assessment. As first described by Nolano et al (15), we found a significant reduction of intraepidermal fiber density in the lower leg in FRDA patients compared to healthy controls. Additionally, by recruiting patients with different GAA1 repeat lengths in our cohort, we observed that the degree of intraepidermal nerve fiber loss was heterogeneous and correlated with the severity of the underlying genetic defect. Notably, the length of the shorter GAA repeat is the major phenotypic determinant in FRDA and the magnitude of the correlation with the IENF density found in this study is similar to that of the well-known correlation between GAA1 repeats and age at onset ($60%). Interestingly, an earlier work by Santoro et al demonstrated a similar correlation between the severity of peripheral large fiber sensory neuropathy and GAA1 repeat length by means of nerve conduction studies and sural nerve biopsy (21) . Similar to our study, they found no correlation between severity of sensory neuropathy and disease duration. Furthermore, they observed stable electrophysiological and biopsy findings in a follow-up examination, which led them to hypothesize a very early but stable involvement of peripheral nerves in FRDA, perhaps due to a defective development (21) . Recently, a neuropathological study by Koeppen et al (22) provided indirect evidence that frataxin deficiency may primarily affect the neural crest derivative boundary cap cells. Boundary cap cells block the "spilling" of central glia in DRGs (23) during neurodevelopment and further differentiate in 2 DRG cell subtypes: the satellite cells and nociceptors (23) , that is, the parent cells of small unmyelinated fibers in peripheral nerve. Although speculative, this notion together with our findings may suggest that small nerve fiber loss in FRDA reflects a primary neurodegenerative process and is not simply an epiphenomenon.
Clinically, epicritic sensory modalities were, as expected, markedly impaired in FRDA, reflecting large fiber sensory neuropathy and DRG pathology. Concerning parameters of small fiber function, in our study only the cold detection threshold was significantly lower in FRDA. Nonetheless, in the thermic sensation evaluation, the CDT is a sensitive and robust measure for small fiber or spinothalamic tract function deficits (24) , while other parameters such as WDT and CPT showed a greater variability, even within healthy subjects. Nolano et al found largely impaired thermic thresholds in the distal leg of their FRDA cohort (15) . These latter findings could be explained by the different characteristics of their cohort as well as by technical differences. Indeed, they examined patients with severe and longstanding disease. Moreover, the study was conducted before the definition of an international standardized protocol and they used a larger Peltier electrode (15 vs 9 cm 2 ) which, by stimulating more nerve fibers, probably influences thermal thresholds. Neuropathic symptoms occurred in some of our patients, but no correlation with IENF density was evident. Interestingly, we observed a reduced innervation of sweat glands in skin biopsies of FRDA and accordingly, in a previous study by our group, up to 65% of FRDA patients reported disturbances of thermoregulation in an autonomic questionnaire (25) . Autonomic symptoms in FRDA have been poorly investigated. In the literature, urinary disturbances are the most reported autonomic symptoms (25, 26) . Little is known about their pathophysiology, but multiple factors are likely to play a role (e.g. pyramidal syndrome because of corticospinal tract involvement, peripheral neuropathy).
In summary, we found a marked small fiber involvement in our FRDA cohort and showed a correlation between the degree of intraepidermal nerve fiber loss and the length of the shorter GAA allele, to date the strongest phenotypic determinant in FRDA. Clinical correlates of small fiber pathology were rather mild, possibly reflecting the marked variability in the severity of biopsy findings. The density of intraepidermal nerve fibers is well defined in healthy subjects. Dynamic changes of IENF density in response to injury may occur and have been well characterized in the setting of several medical conditions affecting peripheral nerves (for a review see [27] ). Punch skin biopsy is a minimally invasive procedure which can be repeated over time to study changes in cutaneous innervation related to disease progression or nerve regeneration (28) (29) (30) . This latter aspect makes the assessment of IENF density an attractive outcome marker in early clinical trials.
Our study was limited to a small patient cohort and we studied intraepidermal nerve fibers at a single site. Nonetheless we recruited a representative patient cohort including patients with different GAA1 expansions, thus allowing us to investigate correlations with clinical features. We decided to perform 1 biopsy at the lower leg because peripheral neuropathy in FRDA is length-dependent, lower extremities are always affected, and we expected to find distally the most marked findings. The evaluation of larger cohorts is advocated to confirm the present results as well as prospective studies that could further explore the potential of IENF density as a disease biomarker in FRDA.
